Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 48 entries
View as:

A Trial to Learn More About an Experimental Gene Therapy Called Bidridistrogene Xeboparvovec (SRP-9003) as a Possible Treatment for Limb Girdle Muscular Dystrophy 2E/R4

Phase: N/A Priority: Normal
NCT ID: NCT06246513 Org: User:
Start: 01/15/24 End: 11/30/29 Due: 11/30/30

A Gene Transfer Single Dose Study to Evaluate the Safety, Tolerability and Efficacy of SRP-9003 in Non-Ambulatory and Ambulatory Participants With Limb Girdle Muscular Dystrophy, Type 2E/R4 (Beta-Sarcoglycan [β-SG] Deficiency)

Phase: N/A Priority: Normal
NCT ID: NCT05876780 Org: User:
Start: 12/19/22 End: 08/28/28 Due: 08/28/29

Efficacy, Safety, and Tolerability Rollover Study of Eteplirsen in Subjects With Duchenne Muscular Dystrophy

Phase: N/A Priority: Normal
NCT ID: NCT01540409 Org: User:
Start: 02/27/12 End: 08/16/17 Due: 08/16/18

A Gene Transfer Therapy Study to Evaluate the Safety of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)

Phase: N/A Priority: Normal
NCT ID: NCT03375164 Org: User:
Start: 01/04/18 End: 04/25/23 Due: 04/25/24

Safety and Efficacy of RESTEN-MP When Used in Conjunction With a Bare Metal Stent in Coronary Arteries

Phase: N/A Priority: Normal
NCT ID: NCT00248066 Org: User:
Start: 09/30/05 End: - Due: -

A Randomized, Double-blind, Placebo-controlled Study of Delandistrogene Moxeparvovec (SRP-9001) for Duchenne Muscular Dystrophy (DMD)

Phase: N/A Priority: Normal
NCT ID: NCT03769116 Org: User:
Start: 12/05/18 End: 08/16/23 Due: 08/16/24

A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical Study

Phase: N/A Priority: Normal
NCT ID: NCT05967351 Org: User:
Start: 09/27/23 End: 11/30/30 Due: 11/30/31

Safety Study of Single Administration Post-exposure Prophylaxis Treatment for Marburg Virus

Phase: N/A Priority: Normal
NCT ID: NCT01353040 Org: User:
Start: 05/31/11 End: 12/31/11 Due: 12/31/12

Two-Part Study for Dose Determination of Vesleteplirsen (SRP-5051) (Part A), Then Dose Expansion (Part B) in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51-Skipping Treatment

Phase: N/A Priority: Normal
NCT ID: NCT04004065 Org: User:
Start: 06/26/19 End: 02/07/25 Due: 02/07/26

An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular Dystrophy

Phase: N/A Priority: Normal
NCT ID: NCT03532542 Org: User:
Start: 08/02/18 End: 07/26/23 Due: 07/26/24

A Study of SRP-9005 in Limb Girdle Muscular Dystrophy Type 2C/R5 Pediatric and Adult Participants

Phase: N/A Priority: Normal
NCT ID: NCT06952686 Org: User:
Start: 06/30/25 End: 03/30/32 Due: 03/30/33

Efficacy Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystrophy Patients

Phase: N/A Priority: Normal
NCT ID: NCT01396239 Org: User:
Start: 07/31/11 End: 06/30/12 Due: 06/30/13

An Exploratory Study of AVI-4020 in Patients With Possible Acute Neuroinvasive West Nile Virus (WNV) Disease

Phase: N/A Priority: Normal
NCT ID: NCT00091845 Org: User:
Start: 11/30/04 End: 11/30/04 Due: 11/30/05

Phase I/II Study of SRP-4053 in DMD Patients

Phase: N/A Priority: Normal
NCT ID: NCT02310906 Org: User:
Start: 01/13/15 End: 03/25/19 Due: 03/25/20

A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)

Phase: N/A Priority: Normal
NCT ID: NCT04626674 Org: User:
Start: 11/23/20 End: 07/31/26 Due: 07/31/27

A Phase 1b Study Evaluating RESTEN-MP in Subjects With Focal de Novo Stenosis

Phase: N/A Priority: Normal
NCT ID: NCT00244647 Org: User:
Start: 08/31/03 End: - Due: -

A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)

Phase: N/A Priority: Normal
NCT ID: NCT05881408 Org: User:
Start: 05/31/23 End: 06/30/28 Due: 06/30/29

Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular Dystrophy

Phase: N/A Priority: Normal
NCT ID: NCT02286947 Org: User:
Start: 11/30/14 End: 03/23/18 Due: 03/23/19

Dose-Ranging Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystrophy (DMD) Patients

Phase: N/A Priority: Normal
NCT ID: NCT00844597 Org: User:
Start: 01/31/09 End: 12/31/10 Due: 12/31/11

Pharmacokinetic Study of a Single Dose of AVI-4126 (RESTEN-NG®) in Cerebral Spinal Fluid

Phase: N/A Priority: Normal
NCT ID: NCT00343148 Org: User:
Start: 06/30/06 End: 06/30/09 Due: 06/30/10

Study of AVI-4065 in Healthy Volunteers and Chronic Active HCV Patients

Phase: N/A Priority: Normal
NCT ID: NCT00229749 Org: User:
Start: 09/30/05 End: 01/31/07 Due: 01/31/08

Pharmacokinetic Study in Cerebral Spinal Fluid After a Single Dose of AVI-4020

Phase: N/A Priority: Normal
NCT ID: NCT00387283 Org: User:
Start: 10/31/06 End: 06/30/09 Due: 06/30/10

A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Imlifidase Infusion in Participants With Duchenne Muscular Dystrophy (DMD) Determined to Have Pre-existing Antibodies to Recombinant Adeno-Associated Virus Serotype (rAAVrh74)

Phase: N/A Priority: Normal
NCT ID: NCT06241950 Org: User:
Start: 01/29/24 End: 10/31/27 Due: 10/31/28

A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON)

Phase: N/A Priority: Normal
NCT ID: NCT03992430 Org: User:
Start: 07/13/20 End: 10/31/26 Due: 10/31/27

A Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7537 in Healthy Adult Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT01593072 Org: User:
Start: 08/31/12 End: 01/31/13 Due: 01/31/14